4basebio partners with TriLink to link DNA and mRNA manufacturing for a Phase I cell therapy trial
A cell therapy program at an unnamed multinational pharmaceutical company will use synthetic DNA and outsourced mRNA manufacturing services. The collaboration brings a novel starting material into clinical supply, but manufacturing benefits and the therapy’s performance remain to be verified by data.